Group 1 - The core point of the article is that 恒瑞医药 has entered into an exclusive licensing agreement with BraveheartBio for its Myosin small molecule inhibitor HRS-1893, leading to a significant increase in its stock price [1] - 恒瑞医药's stock rose by 3.5% to HKD 84.2, with a trading volume of HKD 155 million [1] - The total amount of 恒瑞医药's three business development (BD) transactions this year has exceeded USD 15 billion [1] Group 2 - Under the agreement, 恒瑞医药 grants BraveheartBio exclusive rights to develop, produce, and commercialize HRS-1893 globally, excluding mainland China, Hong Kong, Macau, and Taiwan [1] - BraveheartBio will pay 恒瑞医药 an upfront payment of USD 65 million, which includes USD 32.5 million in cash and an equivalent of USD 32.5 million in BraveheartBio equity, along with a USD 10 million milestone payment after technology transfer [1] - Additionally, 恒瑞医药 could receive up to USD 1.013 billion in milestone payments related to clinical development and sales, as well as corresponding sales royalties [1]